Jerome Cantor

Title: Jerome Cantor and a Faster Method for Measuring COPD Biomarkers.

Introduction

Jerome Cantor is an inventor associated with St. John’s University in Queens, New York. His work includes a patent for measuring desmosine, a biomarker of elastin degradation, to assess chronic obstructive pulmonary disease (COPD).

Latest Patents

Cantor’s patent, “Method for Measuring COPD Biomarkers,” describes using desmosine measurements to evaluate the extent and progression of COPD. The method may support COPD screening and provide a real-time way to assess the effectiveness of drug treatments, potentially complementing less sensitive approaches such as pulmonary function studies and computed tomography.

The invention also aims to shorten the time required to detect desmosine in liquid chromatography–tandem mass spectrometry (LC-MS-MS) assays. Because it can use LC-MS-MS equipment without modification, the method may be suitable for laboratories that already use the technology, including forensic facilities investigating whether undiagnosed COPD contributed to a death. Cantor is associated with 1 patent.

Career Highlights

Cantor’s patent work connects biomarker measurement with potential applications in disease screening, treatment monitoring, and forensic analysis. His affiliation with St. John’s University places this work within a university research setting.

Collaborations

Cantor’s coworker is Michael Fagiola. The available information identifies their professional connection but does not specify the nature of their collaboration.

Conclusion

Jerome Cantor’s patented method focuses on making desmosine measurement faster and more accessible, with potential uses in evaluating COPD progression, monitoring treatment, and supporting forensic investigations.